A Single Ascending Dose Study in Healthy Participants and Multiple Dose Study of JNJ-55920839 in Participants With Mild to Moderate Systemic Lupus Erythematosus

NCT02609789 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

72

Enrollment

INDUSTRY

Sponsor class

Conditions

Systemic Lupus Erythematosus
Healthy

Interventions

DRUG: JNJ-55920839
DRUG: Placebo

Sponsor

Janssen Research & Development, LLC